Clinical Trials Using FGFR Inhibitor INCB054828
Clinical trials are research studies that involve people. The clinical trials on this list are studying FGFR Inhibitor INCB054828. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Location: 17 locations
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced / Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced / metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.
Location: 8 locations
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
Location: 7 locations
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid / Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid / lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
Location: 5 locations
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF / FGFR alterations.
Location: 4 locations
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.
Location: OHSU Knight Cancer Institute, Portland, Oregon
Pemigatinib before Surgery for the Treatment of Recurrent Low- or Intermediate Risk Non-Muscle Invasive Bladder Cancer
This phase II trial studies how well pemigatinib before surgery works in treating patients with low- or intermediate risk non-muscle invasive bladder cancer that has come back (recurrent). Fibroblast growth factor receptor (FGFR) genes are genes that, when altered, can lead to and promote the growth of cancer in patients. In non-muscle invasive bladder cancer, FGFR3 gene mutations have been seen in patients with recurrent bladder tumors and a prior history of low or intermediate risk tumors. Pemigatinib is an orally administered drug that inhibits fibroblast growth factor receptors 1, 2, and 3 (FGFR 1 / 2 / 3). Pemigatinib followed by surgery may be an effective treatment in patients with low- and intermediate risk non-muscle invasive bladder cancer.
Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland